SAN FRANCISCO, Oct. 2, 2018 /PRNewswire/ -- Nektar
Therapeutics (Nasdaq: NKTR) today announced that ten clinical and
preclinical data presentations across its immuno-oncology portfolio
will be presented at the upcoming Society for Immunotherapy of
Cancer (SITC) Annual Meeting, which is being held from November 7 to November 11, 2018, at the Walter E.
Washington Convention Center in Washington, D.C.
In addition to the ten data abstracts, Deborah Charych, Ph.D., Executive Director,
Research Biology, Nektar Therapeutics will give an invited
presentation "Harnessing Potent Immune Agonist Pathways through
Kinetic Engineering," which will be featured during the Cytokines
Reinvented Session on November 9,
2018.
"We are excited that ten separate abstracts with Nektar pipeline
molecules have been accepted for presentation at this year's SITC
meeting," said Jonathan Zalevsky,
Ph.D., Senior Vice President and Chief Scientific Officer at
Nektar. "These abstracts showcase the progress we've made across
our portfolio ranging from clinical and preclinical stage programs
and spanning both large molecule and small molecule modalities. The
data presented will also demonstrate the progress we've made across
our portfolio characterizing how these unique mechanisms can be
used to target and activate multiple elements of the immune system.
These preclinical and clinical data reinforce the potential of our
therapies to serve as foundational therapies in
immuno-oncology."
Oral Presentation:
Abstract Title: "Immune monitoring after NKTR-214 plus
nivolumab (PIVOT-02) in previously untreated patients with
metastatic Stage IV melanoma"
Abstract: #O4
Presenter: Dr. Adi Diab, MD
Anderson Cancer Center
Session Title: Cytokines Reinvented
Date: Friday, November 9,
2018, 5:05 p.m. – 6:30 p.m. Eastern Standard Time
Poster Presentations:
Combination Therapy
Abstract #P364: "Systemic anti-tumor immunity and
immune memory formation by a novel TLR7/8 targeting agent NKTR-262
combined with CD122-biased immunostimulatory cytokine
NKTR-214", Kivimae, S., et al.
Session Date and Time: Friday,
November 9th from 8
a.m. – 8 p.m. and Saturday, November 10th from
8 a.m. – 8:30
p.m. Eastern Standard Time
Abstract #P378: "NKTR-214 (CD122-biased agonist) and
NKTR-262 (TLR7/8 agonist) combination treatment pairs local innate
immune activation with systemic CD8+ T cell expansion to enhance
anti-tumor immunity", Rolig, A., et al.
Session Date and Time: Friday,
November 9th from 8
a.m. – 8 p.m. and Saturday, November 10th from
8 a.m. – 8:30
p.m. Eastern Standard Time
Abstract #P368: "Combination of a Dipeptidyl Peptidase
Inhibitor BXCL701 and Biased CD122 Agonist NKTR-214 with Anti-PD1
Provides Functional Immunological Memory through Inflammatory Cell
Death", MacDougall, J., et al.
Session Date and Time: Friday,
November 9th from 8
a.m. – 8 p.m. and Saturday, November 10th from 8 a.m. – 8:30 p.m. Eastern
Standard Time
Abstract #P348: "Survival and immune modulation in
homologous recombination deficient murine ovarian tumors using the
PARP inhibitor, rucaparib and immune agonist, NKTR-214",
Charych, D., et al.
Session Date and Time: Friday,
November 9th from 8
a.m. – 8 p.m. and Saturday, November 10th from
8 a.m. – 8:30
p.m. Eastern Standard Time
Cytokines in Anti-Tumor Immunity
Abstract #P418: "Pre-clinical investigation of
NKTR-255, a polymer-conjugated IL-15 with a potent NK cell
dependent anti-tumor efficacy", Miyazaki, T., et al.
Session Date and Time: Friday,
November 9th from 8
a.m. – 8 p.m. and Saturday, November 10th from
8 a.m. – 8:30
p.m. Eastern Standard Time
Abstract #P419: "NKTR-214 in combination with
radiation produces a potent in situ vaccine in the syngeneic B78
melanoma model", Sondel, P., et al.
Session Date and Time: Friday,
November 9th from 8
a.m. – 8 p.m. and Saturday, November 10th from
8 a.m. – 8:30
p.m. Eastern Standard Time
Abstract #P422: "A polymer-associated human IL-15
(NKTR-255) has optimized biological activity and unique mechanisms
of action on CD8 T Cells and NK Cells", Robinson T., et al.
Session Date and Time: Friday,
November 9th from 8
a.m. – 8 p.m. and Saturday, November 10th from
8 a.m. – 8:30
p.m. Eastern Standard Time
Abstract #P424: "NKTR-214, an engineered IL-2,
selectively depletes intratumoral Tregs and expands
immunotherapy-induced effector T cell responses", Sharma, M.,
et al.
Session Date and Time: Friday,
November 9th from 8
a.m. – 8 p.m. and Saturday, November 10th from
8 a.m. – 8:30
p.m. Eastern Standard Time
Mechanisms of Resistance to Immunotherapy
Abstract #P557: "Overcoming genetically-based
resistance mechanisms to PD-1 blockade", Torrejon, D., et
al.
Session Date and Time: Friday,
November 9th from 8
a.m. – 8 p.m. and Saturday, November 10th from
8 a.m. – 8:30
p.m. Eastern Standard Time
Company to Host Webcast Conference Call at SITC
The
company will host a webcast conference call with melanoma
specialists and company management on Saturday, November 10th at
9:30 a.m. Eastern time during the
SITC conference following presentation of data. The webcast
conference call will be accessible from the Investor Events page of
Nektar's website at
http://ir.nektar.com/events-and-presentations/events.
About Nektar
Nektar Therapeutics is a research-based
development stage biopharmaceutical company whose mission is to
discover and develop innovative medicines to address the unmet
medical needs of patients. Our R&D pipeline of new
investigational medicines includes treatments for cancer,
auto-immune disease and chronic pain. We leverage Nektar's
proprietary and proven chemistry platform in the discovery and
design of our new therapeutic candidates. Nektar is headquartered
in San Francisco, California, with
additional operations in Huntsville,
Alabama and Hyderabad,
India. Further information about the company and its drug
development programs and capabilities may be found online at
http://www.nektar.com.
Cautionary Note Regarding Forward-Looking
Statements
This press release contains forward-looking
statements which can be identified by words such as: "will,"
"believe," "can," "serve" and similar references to future periods.
Examples of forward-looking statements include, among others,
statements we make regarding the therapeutic potential of our
pipeline molecules alone or in combination with other therapeutic
agents, and the availability of results and outcomes from clinical
and preclinical studies of our new drug candidates.
Forward-looking statements are neither historical facts nor
assurances of future performance. Instead, they are based only on
our current beliefs, expectations and assumptions regarding the
future of our business, future plans and strategies, anticipated
events and trends, and other future conditions. Because
forward-looking statements relate to the future, they are subject
to inherent uncertainties, risks and changes in circumstances that
are difficult to predict and many of which are outside of our
control. Our actual results may differ materially from those
indicated in the forward-looking statements. Therefore, you should
not rely on any of these forward-looking statements. Important
factors that could cause our actual results to differ materially
from those indicated in the forward-looking statements include,
among others: (i) our statements regarding the therapeutic
potential of our pipeline molecules are based on preclinical and
clinical findings and observations; (ii) NKTR-214 and most of our
pipeline molecules are in early stage clinical development and the
risk of failure remains high and failure can unexpectedly occur at
any stage for one or more of the cancer indications being studied
prior to regulatory approval due to lack of sufficient efficacy,
safety considerations or other factors that impact drug
development; (iii) data reported from ongoing preclinical and
clinical trials are necessarily interim data only and the final
results will change based on continuing observations; (iv)
scientific discovery of new medical breakthroughs is an inherently
uncertain process and the future success of potential new drug
candidates (such as NKTR-214, NKTR-262 and NKTR-255) is therefore
very uncertain and unpredictable; (v) patents may not issue from
our patent applications for our drug candidates, patents that have
issued may not be enforceable, or additional intellectual property
licenses from third parties may be required; and (vi) certain other
important risks and uncertainties set forth in Nektar's Quarterly
Report on Form 10-Q filed with the Securities and Exchange
Commission on August 9, 2018. Any
forward-looking statement made by us in this press release is based
only on information currently available to us and speaks only as of
the date on which it is made. We undertake no obligation to update
any forward-looking statement, whether written or oral, that may be
made from time to time, whether as a result of new information,
future developments or otherwise.
Contact:
For Investors:
Jennifer Ruddock of Nektar
Therapeutics
415-482-5585
Jodi Sievers of Nektar
Therapeutics
415-482-5593
For Media:
Dan Budwick of 1AB
973-271-6085
dan@1abmedia.com
View original
content:http://www.prnewswire.com/news-releases/nektar-therapeutics-announces-ten-abstracts-accepted-for-presentation-at-the-2018-society-for-immunotherapy-of-cancer-sitc-annual-meeting-300722461.html
SOURCE Nektar Therapeutics